高コレステロール血症治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Hypercholesterolemia Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Drug profiles

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Clinical application
• Treatment guidelines
• Key buying criteria

PART 05: Hypercholesterolemia: An overview
• History of hypercholesterolemia
• Hypercholesterolemia management market dynamics
• Hypercholesterolemia prescription landscape
• Management of hypercholesterolemia
• Epidemiology
• Unmet medical needs and role of PCSK9 and CETP inhibitors

PART 06: Pipeline portfolio
• Information on pipeline candidates

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: segmentation by type of disease
• FH
• Non-FH

PART 09: Market segmentation by MOA
• HMG-CoA reductase inhibitors
• Fibric acid derivatives
• Nicotinic acid
• Bile acid sequestrants
• Other

PART 10: Market segmentation by drug class
• Statins
• Non-statins

PART 11: Geographical segmentation
• Global hypercholesterolemia drugs market by geographical segmentation 2015-2020
• Hypercholesterolemia drugs market in Americas
• Hypercholesterolemia drugs market in EMEA
• Hypercholesterolemia drugs market in APAC

PART 12: Market drivers
• Increasing risk of CVDs
• Rising prevalence of chronic diseases
• Promising pipeline of drugs
• Change in ATP guidelines for management of hypercholesterolemia
• Growing older population

PART 13: Impact of drivers

PART 14: Market challenges
• Loss of patent exclusivity of branded therapies
• Drawbacks associated with current therapies
• High cost of therapy
• Stringent regulatory guidelines
• Lack of proper diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Expected entry of cost-effective OTC versions
• Increasing use of statins
• Increased use of combination therapies
• Consideration of lifestyle management in ATP guidelines

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015

PART 18: Key vendor analysis
• AbbVie
• Aegerion Pharmaceuticals
• AstraZeneca
• Merck
• Pfizer
• Sanofi
• Other prominent vendors

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Different class of lipoproteins
Exhibit 03: Evaluation of lipoprotein levels based on ATP III classification
Exhibit 04: Key buying criteria for hypercholesterolemia drugs
Exhibit 05: Timeline of cholesterol lowering drugs
Exhibit 06: Market dynamics for hypercholesterolemia
Exhibit 07: Prescription landscape for statins 2015
Exhibit 08: Prescription landscape for ezetimibe 2015
Exhibit 09: Prescription landscape for other classes 2015
Exhibit 10: Distribution of cholesterol-lowering medication for individuals above 40 years
Exhibit 11: Percentage use of prescription cholesterol-lowering medication in US for various indications 2015
Exhibit 12: Treatment of hypercholesterolemia
Exhibit 13: Pharmacological treatment of hypercholesterolemia
Exhibit 14: High cholesterol levels by race and ethnicity in US 2015
Exhibit 15: PCSK9 inhibitors in preclinical and clinical development 2015
Exhibit 16: Pipeline portfolio: Global hypercholesterolemia drugs market
Exhibit 17: Pipeline share of hypercholesterolemia drugs
Exhibit 18: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Classification of hyperlipidemia
Exhibit 21: Global hypercholesterolemia market segmentation by MOA
Exhibit 22: Global hypercholesterolemia market segmentation by MoA 2015
Exhibit 23: Global hypercholesterolemia drugs market segmentation by drug class
Exhibit 24: Global hypercholesterolemia drugs market by drug class 2015 (% share)
Exhibit 25: Hypercholesterolemia drugs market revenue by drug class 2015-2020 ($ billions)
Exhibit 26: Global statin market 2015-2020 ($ billions)
Exhibit 27: Number of prescriptions for statins in US
Exhibit 28: Usage of statins for hypercholesterolemia in US 2015
Exhibit 29: Usage of statins for hypercholesterolemia in UK 2015
Exhibit 30: Global non-statins market 2015-2020 ($ billions)
Exhibit 31: Number of prescriptions for non-statins in US
Exhibit 32: Global hypercholesterolemia drugs market: YoY growth and revenue based on drug class 2015-2020
Exhibit 33: Segmentation of global hypercholesterolemia drugs markets by geography 2015
Exhibit 34: Hypercholesterolemia drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 35: Percentage share of hypercholesterolemia drugs market by geography 2015-2020 (%)
Exhibit 36: Hypercholesterolemia drugs market in Americas 2015-2020 ($ billions)
Exhibit 37: Share of hypercholesterolemia drugs market in Americas by country 2015
Exhibit 38: Hypercholesterolemia drugs market in EMEA 2015-2020 ($ billions)
Exhibit 39: Hypercholesterolemia drugs market in APAC 2015-2020 ($ billions)
Exhibit 40: Global hypercholesterolemia drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 41: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Arguments for and against OTC switch by pharmaceutical companies and regulatory organizations
Exhibit 45: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 46: Revenue from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 47: AbbVie: YoY revenue and growth rate of lipid franchise portfolio 2013-2015 ($ millions)
Exhibit 48: Key takeaways
Exhibit 49: Aegerion: YoY revenue and growth rate of JUXTAPID 2013-2015 ($ millions)
Exhibit 50: Key takeaways
Exhibit 51: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 52: AstraZeneca: Geographic segmentation of Crestor 2015 by revenue
Exhibit 53: Key takeaways
Exhibit 54: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 55: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 56: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 57: Merck: Key takeaways
Exhibit 58: Pfizer: YoY revenue and growth rate of Lipitor 2013-2015 ($ billions)
Exhibit 59: Pfizer: Geographic segmentation of Lipitor by revenue 2015
Exhibit 60: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 61: Key takeaways
Exhibit 62: Sanofi: Key takeaways


【レポート販売概要】

■ タイトル:高コレステロール血症治療薬の世界市場2016-2020
■ 英文:Global Hypercholesterolemia Drugs Market 2016-2020
■ 発行日:2016年7月25日
■ 調査会社:Technavio
■ 商品コード:IRTNTR9069
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。